Vestmark Advisory Solutions Inc. Has $2.35 Million Stock Holdings in Sanofi $SNY

Vestmark Advisory Solutions Inc. trimmed its holdings in Sanofi (NASDAQ:SNY) by 31.2% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 48,636 shares of the company’s stock after selling 22,096 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Sanofi were worth $2,350,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Accent Capital Management LLC bought a new stake in Sanofi in the first quarter worth $29,000. Eastern Bank lifted its stake in shares of Sanofi by 121.0% in the first quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after buying an additional 300 shares during the last quarter. Ameritas Advisory Services LLC bought a new stake in shares of Sanofi during the 2nd quarter worth $28,000. Banque Transatlantique SA bought a new stake in shares of Sanofi during the 1st quarter worth $33,000. Finally, Brentview Investment Management LLC acquired a new position in Sanofi during the 1st quarter worth $42,000. Institutional investors own 14.03% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on SNY. Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $56.00 to $58.00 in a report on Monday, September 8th. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $62.67.

Sanofi Trading Up 0.3%

Shares of SNY stock opened at $49.66 on Monday. The company has a market capitalization of $121.94 billion, a P/E ratio of 11.63, a P/E/G ratio of 1.38 and a beta of 0.49. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12. The company has a quick ratio of 0.94, a current ratio of 1.06 and a debt-to-equity ratio of 0.16. The firm has a 50-day moving average price of $48.64 and a 200 day moving average price of $49.46.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Friday, October 24th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.10. The business had revenue of $14.53 billion for the quarter, compared to analyst estimates of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.Sanofi’s revenue for the quarter was down 7.5% on a year-over-year basis. During the same period in the prior year, the company earned $2.25 EPS. Research analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.